|

HRS-4642 Clinical Trials

4 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 2: 2Phase 1/2: 2

Top Sponsors

  • Zhejiang University1
  • Shanghai Zhongshan Hospital1
  • Jiangsu HengRui Medicine Co., Ltd.1
  • Fudan University1

Indications

  • Cancer4
  • Pancreatic Cancer2
  • Metastatic Pancreatic Carcinoma1
  • Advanced Solid Tumors1

Other4 trials

A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
Phase 1/2
An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
Phase 2
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/2
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.